PDF(Pubmed)
Abstract：
BACKGROUND: Bictegravir (BIC), a recently introduced integrase inhibitor, is available in a single tablet regimen with tenofovir alafenamide (TAF) and emtricitabine (FTC) (BIC-STR). This study aimed to describe a real-life experience with BIC-STR.
METHODS: We retrospectively analyzed the data of people living with HIV (PLWH) on antiretroviral therapy (ART) with BIC-STR followed by the Clinic of Infectious Diseases of Perugia (Perugia, Italy) from September 2019 to February 2023.
RESULTS: 270 PLWH were enrolled with a median follow-up time on BIC-STR of 2.2 years (IQR 1.2-2.7). In the overall population, in treatment-experienced (N = 242), in treatment-naïve (N = 28), and in population with age > 60 years old (N = 86), we observed that CD4 cell count improved in absolute number, percentage and CD4/CD8 ratio, under BIC-STR. Patients with viremia < 50 cp/mL increased in all groups. In the overall population, previous ART with TAF and nadir CD4 cell count favored immunological recovery. In the ART-experienced group, time in therapy with BIC-STR was associated with HIV-RNA undetectability. In the older group, previous opportunistic infection and advanced age were associated with lower CD4 count.
CONCLUSIONS: BIC-STR was demonstrated, in real-life, to be a valid option for a switch, such as initial ART.
METHODS: We retrospectively analyzed the data of people living with HIV (PLWH) on antiretroviral therapy (ART) with BIC-STR followed by the Clinic of Infectious Diseases of Perugia (Perugia, Italy) from September 2019 to February 2023.
RESULTS: 270 PLWH were enrolled with a median follow-up time on BIC-STR of 2.2 years (IQR 1.2-2.7). In the overall population, in treatment-experienced (N = 242), in treatment-naïve (N = 28), and in population with age > 60 years old (N = 86), we observed that CD4 cell count improved in absolute number, percentage and CD4/CD8 ratio, under BIC-STR. Patients with viremia < 50 cp/mL increased in all groups. In the overall population, previous ART with TAF and nadir CD4 cell count favored immunological recovery. In the ART-experienced group, time in therapy with BIC-STR was associated with HIV-RNA undetectability. In the older group, previous opportunistic infection and advanced age were associated with lower CD4 count.
CONCLUSIONS: BIC-STR was demonstrated, in real-life, to be a valid option for a switch, such as initial ART.
摘要：
背景：Bictegravir（BIC），最近推出的整合酶抑制剂，替诺福韦艾拉酚胺（TAF）和恩曲他滨（FTC）（BIC-STR）的单一片剂方案。本研究旨在描述BIC-STR的真实体验。
方法：我们回顾性分析了使用BIC-STR进行抗逆转录病毒治疗（ART）的HIV感染者（PLWH）的数据，然后是佩鲁贾传染病诊所（佩鲁贾，意大利）从2019年9月到2023年2月。
结果：270PLWH入组，BIC-STR的中位随访时间为2.2年（IQR1.2-2.7）。在总人口中,在治疗经验中（N=242），在治疗初期（N=28），在年龄>60岁的人群中(N=86)，我们观察到CD4细胞计数的绝对数量提高，百分比和CD4/CD8比率，根据BIC-STR。所有组病毒血症<50cp/mL的患者均增加。在总人口中,先前使用TAF和最低点CD4细胞计数的ART有利于免疫恢复。在有ART经验的小组中，BIC-STR治疗时间与HIV-RNA不可检测性相关.在老年群体中，既往机会性感染和高龄与CD4计数降低相关.
结论：证明了BIC-STR，在现实生活中,是开关的有效选项，比如最初的艺术。
方法：我们回顾性分析了使用BIC-STR进行抗逆转录病毒治疗（ART）的HIV感染者（PLWH）的数据，然后是佩鲁贾传染病诊所（佩鲁贾，意大利）从2019年9月到2023年2月。
结果：270PLWH入组，BIC-STR的中位随访时间为2.2年（IQR1.2-2.7）。在总人口中,在治疗经验中（N=242），在治疗初期（N=28），在年龄>60岁的人群中(N=86)，我们观察到CD4细胞计数的绝对数量提高，百分比和CD4/CD8比率，根据BIC-STR。所有组病毒血症<50cp/mL的患者均增加。在总人口中,先前使用TAF和最低点CD4细胞计数的ART有利于免疫恢复。在有ART经验的小组中，BIC-STR治疗时间与HIV-RNA不可检测性相关.在老年群体中，既往机会性感染和高龄与CD4计数降低相关.
结论：证明了BIC-STR，在现实生活中,是开关的有效选项，比如最初的艺术。
